Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Drops By 79.9%

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 316,392 shares, a drop of 79.9% from the July 30th total of 1,577,365 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average trading volume of 2,216,181 shares, the days-to-cover ratio is currently 0.1 days.

Moleculin Biotech Price Performance

Shares of MBRX traded up $0.09 during mid-day trading on Thursday, hitting $0.69. The stock had a trading volume of 1,484,548 shares, compared to its average volume of 2,436,552. Moleculin Biotech has a 52 week low of $0.16 and a 52 week high of $15.75. The business has a fifty day moving average price of $1.66 and a 200-day moving average price of $2.25. The firm has a market cap of $13.42 million, a P/E ratio of -0.10 and a beta of 1.83.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.15. As a group, research analysts expect that Moleculin Biotech will post -3.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MBRX has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Wall Street Zen upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.00.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.